Oxbryta (Voxelotor)
Hemoglobin S polymerization inhibitor for sickle cell disease
Oxbryta (voxelotor) is a first-in-class hemoglobin S polymerization inhibitor approved for the treatment of hemolytic anemia associated with sickle cell disease in adults and children aged 12 years and older. By improving how sickle hemoglobin binds oxygen, Oxbryta reduces the destruction of red blood cells and helps maintain healthier hemoglobin levels. It can be used alone or in combination with hydroxycarbamide (hydroxyurea).
Quick Facts: Oxbryta
Key Takeaways
- Oxbryta is specifically designed for sickle cell disease and works by preventing hemoglobin S from polymerizing, which reduces red blood cell sickling and destruction.
- The standard adult and adolescent dose is 1500 mg (three 500 mg tablets) taken once daily by mouth, with or without food.
- Common side effects include headache, diarrhea, abdominal pain, nausea, and rash. Serious but rare reactions include DRESS syndrome and angioedema.
- Oxbryta may interact with strong CYP3A4 inducers (such as rifampicin and carbamazepine) and sensitive CYP3A4 substrates (such as sirolimus and tacrolimus).
- Patients receiving blood transfusions should inform their healthcare provider, as Oxbryta can affect the interpretation of certain blood tests.
What Is Oxbryta and What Is It Used For?
Quick Answer: Oxbryta (voxelotor) is a prescription medicine used to treat hemolytic anemia in people aged 12 years and older with sickle cell disease. It works by stabilizing the oxygenated form of hemoglobin S, reducing red blood cell sickling and premature destruction.
Sickle cell disease (SCD) is a group of inherited blood disorders that affects the hemoglobin molecule inside red blood cells. Hemoglobin is the protein responsible for carrying oxygen from the lungs to tissues throughout the body. In people with SCD, an abnormal form of hemoglobin known as hemoglobin S (HbS) is produced. When hemoglobin S releases its oxygen in the tissues, the protein molecules stick together and form long, rigid chains. This process, called polymerization, distorts the shape of red blood cells from their normal round, flexible disc shape into a rigid crescent or sickle shape.
These sickle-shaped red blood cells cannot deliver oxygen to tissues as efficiently as healthy red blood cells. Furthermore, they are fragile and break down far more rapidly than normal red blood cells, a process known as hemolysis. While healthy red blood cells typically survive for about 120 days, sickled red blood cells may survive only 10 to 20 days. This accelerated destruction leads to a chronic shortage of red blood cells known as hemolytic anemia, which is one of the hallmark features of sickle cell disease.
Oxbryta contains the active substance voxelotor, which represents a novel therapeutic approach to sickle cell disease. Voxelotor binds directly to hemoglobin S with high affinity, stabilizing its oxygenated state. By keeping hemoglobin S in its oxygen-carrying form, voxelotor prevents the polymerization cascade that leads to sickling. This mechanism of action is fundamentally different from other sickle cell treatments: rather than reducing the proportion of hemoglobin S (as hydroxycarbamide does by inducing fetal hemoglobin production), voxelotor directly modifies how existing hemoglobin S behaves.
The clinical benefits of this mechanism are significant. By preventing sickling, Oxbryta improves red blood cell survival and function. In the pivotal HOPE trial, patients treated with voxelotor 1500 mg daily showed significant increases in hemoglobin levels compared to placebo, with improvements often seen as early as two weeks into treatment. Additionally, markers of hemolysis such as indirect bilirubin and reticulocyte count improved, indicating reduced red blood cell destruction.
Oxbryta is approved for use in adults and children aged 12 years and older with sickle cell disease, regardless of the specific genotype (HbSS, HbSC, HbS-beta thalassemia, and others). It can be used as monotherapy or in combination with hydroxycarbamide (also known as hydroxyurea), which is the most widely used disease-modifying treatment for SCD. The combination approach allows clinicians to target multiple aspects of sickle cell pathophysiology simultaneously.
What Should You Know Before Taking Oxbryta?
Quick Answer: Do not take Oxbryta if you are allergic to voxelotor or any of its ingredients. Tell your doctor about any kidney or liver problems. If you experience signs of severe allergic reaction or widespread skin rash with fever, stop taking Oxbryta and seek medical attention immediately.
Contraindications
Oxbryta is contraindicated in patients with a known hypersensitivity to voxelotor or to any of the excipients contained in the formulation. Hypersensitivity reactions, including angioedema, have been reported during post-marketing surveillance. If you have previously experienced an allergic reaction to this medicine, you must not take it again under any circumstances.
Warnings and Precautions
Before starting treatment with Oxbryta, it is important to discuss your complete medical history with your healthcare provider. Several conditions require special attention:
- Severe kidney problems: If you have severe renal impairment, your doctor should evaluate whether Oxbryta is appropriate for you. Limited data are available for patients with severe kidney disease, and dose adjustments may be necessary.
- Severe liver problems: Patients with severe hepatic impairment may require a dose reduction. Your doctor will assess liver function and adjust the Oxbryta dose accordingly, as the medication is primarily metabolized by the liver.
- Allergic reactions: Stop taking Oxbryta immediately and seek emergency medical care if you develop symptoms of a serious allergic reaction, including skin rash (such as hives or urticaria), difficulty breathing, or swelling of the face, lips, eyelids, or throat (angioedema).
- DRESS syndrome: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in association with Oxbryta treatment. This is a serious and potentially life-threatening condition characterized by widespread skin rash, high fever, and enlarged lymph nodes, sometimes with involvement of internal organs. If you notice any of these symptoms, stop taking Oxbryta immediately and seek urgent medical attention.
- Blood transfusions and laboratory tests: Oxbryta can affect the interpretation of certain blood tests, particularly measurements of hemoglobin levels and hemoglobin fractions (such as HbS percentage). If you receive blood transfusions, inform your healthcare team that you are taking this medication so that appropriate adjustments can be made when interpreting your laboratory results.
Stop taking Oxbryta and seek emergency medical care immediately if you experience: widespread skin rash with fever and swollen lymph nodes (possible DRESS syndrome), difficulty breathing, or swelling of the face, lips, or throat (angioedema). These are serious reactions that require immediate medical attention.
Children Under 12 Years
Oxbryta is not recommended for children under 12 years of age due to insufficient clinical data in this age group. Clinical trials establishing the safety and efficacy of voxelotor were conducted in patients aged 12 years and older. If you are a parent or caregiver considering this medication for a younger child, discuss alternative treatment options with a pediatric hematologist.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Oxbryta. There are limited data on the use of voxelotor during pregnancy, and your doctor will help you weigh the potential benefits against the possible risks. The decision to continue or discontinue treatment during pregnancy should be made in close consultation with your healthcare provider.
Breastfeeding is not recommended during treatment with Oxbryta. It is not known whether voxelotor passes into breast milk or whether it could affect a nursing infant. If you are breastfeeding, discuss alternative feeding options with your doctor before starting this medication.
Driving and Operating Machinery
Oxbryta has no or negligible effect on the ability to drive or use machines. No specific precautions are necessary in this regard.
Oxbryta contains less than 1 mmol (23 mg) of sodium per dose of three tablets, meaning it is essentially sodium-free. This is relevant for patients on a controlled sodium diet.
How Does Oxbryta Interact with Other Drugs?
Quick Answer: Oxbryta can interact with several medications, particularly strong CYP3A4 inducers (which can reduce its effectiveness) and sensitive CYP3A4 substrates (whose levels may be increased). Always inform your doctor about all medicines you are taking.
Voxelotor is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. It also has the potential to inhibit CYP3A4 to some extent. This means that other drugs which either induce or are metabolized by CYP3A4 can interact with Oxbryta, potentially altering the effectiveness or safety profile of either medication.
It is essential to inform your healthcare provider about all medicines you are currently taking, have recently taken, or plan to take, including prescription medications, over-the-counter drugs, herbal supplements, and vitamins. Some interactions can significantly affect how Oxbryta works or increase your risk of experiencing adverse effects.
Major Interactions
The following medications have clinically significant interactions with Oxbryta and require careful management:
| Drug | Type | Effect | Clinical Action |
|---|---|---|---|
| Rifampicin | Strong CYP3A4 inducer | May significantly reduce voxelotor blood levels and efficacy | Avoid combination or adjust dose |
| Phenobarbital | Strong CYP3A4 inducer | May significantly reduce voxelotor blood levels | Avoid combination or adjust dose |
| Carbamazepine | Strong CYP3A4 inducer | May significantly reduce voxelotor blood levels | Avoid combination or adjust dose |
| Phenytoin | Strong CYP3A4 inducer | May significantly reduce voxelotor blood levels | Avoid combination or adjust dose |
| St. John's Wort | Strong CYP3A4 inducer (herbal) | May significantly reduce voxelotor blood levels | Avoid combination |
Minor Interactions
The following medications may be affected by Oxbryta due to its CYP3A4 inhibitory activity. Dose adjustments or increased monitoring may be necessary:
| Drug | Type | Effect | Clinical Action |
|---|---|---|---|
| Sirolimus | CYP3A4 substrate (immunosuppressant) | Voxelotor may increase sirolimus levels | Monitor levels; adjust dose as needed |
| Tacrolimus | CYP3A4 substrate (immunosuppressant) | Voxelotor may increase tacrolimus levels | Monitor levels; adjust dose as needed |
| Alfentanil | Sensitive CYP3A4 substrate (opioid) | Voxelotor may increase alfentanil levels | Inform anesthesiologist before surgery |
If you are scheduled for any medical examination or surgery, always inform your healthcare team that you are taking Oxbryta. This is particularly important when general anesthesia is required, as the interaction with alfentanil and other anesthetic agents metabolized by CYP3A4 may necessitate dose modifications.
What Is the Correct Dosage of Oxbryta?
Quick Answer: The recommended dose for adults and children aged 12 years and older is 1500 mg (three 500 mg tablets) taken once daily by mouth. Tablets should be swallowed whole with water and can be taken with or without food.
Always take Oxbryta exactly as your doctor has prescribed. Consistency is key to maintaining therapeutic drug levels and achieving optimal clinical benefit. Do not change your dose or stop taking this medicine without first consulting your healthcare provider.
Adults and Adolescents (12 Years and Older)
Standard Dosing
Dose: 1500 mg (three 500 mg film-coated tablets) taken once daily
Route: Oral administration
Timing: Take at approximately the same time each day
With food: Can be taken with or without food
Important: Swallow tablets whole with a glass of water. Do not split, crush, or chew the tablets as they have an unpleasant taste.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (18+ years) | 1500 mg (3 × 500 mg) | Once daily | No dose adjustment for mild-moderate renal/hepatic impairment |
| Adolescents (12–17 years) | 1500 mg (3 × 500 mg) | Once daily | Same dose as adults |
| Severe hepatic impairment | Reduced dose per physician | Once daily | Doctor will determine appropriate dose |
| Children under 12 | Not recommended | N/A | Insufficient clinical data |
Missed Dose
If you forget to take a dose of Oxbryta, do not take a double dose to make up for the missed one. Simply continue with your regular dosing schedule the following day. Missing an occasional dose is unlikely to have a significant impact on your treatment, but it is important to try to take your medication consistently every day for optimal results. Setting a daily alarm or pairing your medication with a routine daily activity can help you remember.
Overdose
If you take more Oxbryta than prescribed, contact your doctor or your local poison control center immediately. While specific data on overdose with voxelotor are limited, taking more than the recommended dose may increase the risk and severity of side effects. There is no specific antidote for voxelotor overdose, and treatment would be supportive based on symptoms.
Do not stop taking Oxbryta unless your doctor advises you to do so. Sickle cell disease is a chronic condition that requires ongoing treatment. Abruptly discontinuing therapy may lead to a return of hemolytic anemia symptoms and could potentially trigger a sickle cell crisis. If you have concerns about your treatment, discuss them with your healthcare provider.
What Are the Side Effects of Oxbryta?
Quick Answer: The most common side effects are headache, diarrhea, abdominal pain, nausea, and rash (each affecting more than 1 in 10 patients). Serious but rare side effects include allergic reactions, DRESS syndrome, and angioedema. Seek immediate medical attention for any severe reactions.
Like all medicines, Oxbryta can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and tend to occur during the first few weeks of treatment. Understanding the possible side effects and their frequency can help you and your healthcare provider make informed decisions about your treatment and recognize symptoms that may require medical attention.
Very Common Side Effects
May affect more than 1 in 10 people
- Headache
- Diarrhea
- Abdominal (stomach) pain
- Nausea
- Rash
Common Side Effects
May affect up to 1 in 10 people
- Pruritus (itching)
Uncommon Side Effects
May affect up to 1 in 100 people
- Allergic reactions (skin rash including hives, shortness of breath, swelling of the face)
Frequency Not Known
Cannot be estimated from available data
- DRESS syndrome (widespread skin rash, high body temperature, enlarged lymph nodes)
- Angioedema (swelling of eyelids, face, and lips)
Stop taking Oxbryta and seek emergency medical care immediately if you experience any of the following: severe allergic reaction with difficulty breathing and facial swelling; widespread skin rash accompanied by high fever and swollen lymph nodes (DRESS syndrome); or sudden swelling of the eyelids, face, or lips (angioedema). These are serious conditions that require prompt treatment.
The gastrointestinal side effects (diarrhea, abdominal pain, nausea) are typically self-limiting and tend to improve as your body adjusts to the medication. If these symptoms persist or become bothersome, discuss management strategies with your doctor. Headache can often be managed with over-the-counter pain relievers, but always check with your pharmacist or doctor before taking additional medications.
If you experience a skin rash while taking Oxbryta, it is important to report it to your healthcare provider promptly. While most rashes are mild and resolve on their own, a rash can occasionally be an early sign of a more serious reaction such as DRESS syndrome. Your doctor will evaluate the rash and determine whether it is safe to continue treatment.
Reporting suspected side effects after a medicine has been authorized is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (such as the EMA in Europe, the FDA in the United States, or the MHRA in the United Kingdom).
How Should You Store Oxbryta?
Quick Answer: Store Oxbryta at room temperature, out of reach of children. No special storage conditions are required. Do not use after the expiry date printed on the bottle and carton.
Keep this medicine out of the sight and reach of children at all times. Accidental ingestion by children can be harmful, and the child-resistant bottle cap is designed as an additional safety measure. Always ensure the cap is properly secured after each use.
Do not use Oxbryta after the expiry date stated on the bottle and outer carton after "EXP." The expiry date refers to the last day of the stated month. Using expired medication may result in reduced effectiveness and could potentially be unsafe.
There are no special storage requirements for Oxbryta. Store it at room temperature, away from excessive heat and moisture. Do not store it in the bathroom, as humidity can affect the medication. The bottle contains a coil and a silica gel desiccant container to help keep the tablets dry — leave these inside the bottle and do not swallow them.
Do not dispose of medicines by pouring them down the drain or throwing them in household waste. Ask your pharmacist about how to properly dispose of medicines you no longer use. These measures help protect the environment and prevent accidental exposure.
What Does Oxbryta Contain?
Quick Answer: Each film-coated tablet contains 500 mg of voxelotor as the active ingredient, along with inactive ingredients including microcrystalline cellulose, croscarmellose sodium, and a film coating.
Understanding what your medication contains can be important, especially if you have known allergies to specific pharmaceutical excipients. Each Oxbryta tablet is precisely formulated to ensure consistent drug delivery and stability.
Active Ingredient
Each film-coated tablet contains 500 mg of voxelotor. Voxelotor is a small-molecule hemoglobin S polymerization inhibitor that was originally developed by Global Blood Therapeutics (now part of Pfizer) under the investigational name GBT440.
Inactive Ingredients (Excipients)
The tablet core and film coating contain the following inactive ingredients:
- Microcrystalline cellulose (E460) — tablet binder and filler
- Croscarmellose sodium (E468) — disintegrant to aid tablet dissolution
- Sodium lauryl sulfate (E487) — wetting agent
- Colloidal anhydrous silica (E551) — anti-caking agent
- Magnesium stearate (E470b) — lubricant
- Polyvinyl alcohol (E1203) — film coating component
- Titanium dioxide (E171) — white colorant in film coating
- Polyethylene glycol (E1521) — plasticizer in film coating
- Talc (E553b) — anti-adherent in film coating
- Yellow iron oxide (E172) — colorant in film coating
Appearance and Packaging
Oxbryta tablets are light yellow to yellow, oval, biconvex film-coated tablets, approximately 18 mm × 10 mm in size, debossed with "GBT 500" on one side. They are supplied in a plastic bottle with a child-resistant closure. Each bottle contains 90 film-coated tablets, along with a coil and a silica gel desiccant container to protect the tablets from moisture. The bottle is packaged in an outer carton.
Frequently Asked Questions About Oxbryta
Oxbryta (voxelotor) is used to treat hemolytic anemia in adults and children aged 12 years and older who have sickle cell disease. Hemolytic anemia occurs when red blood cells are destroyed faster than the body can replace them, leading to low hemoglobin levels and symptoms such as fatigue, weakness, and shortness of breath. Oxbryta works by preventing the sickling of red blood cells, which helps them survive longer and carry oxygen more effectively.
Oxbryta and hydroxycarbamide (hydroxyurea) work through different mechanisms. Hydroxycarbamide increases the production of fetal hemoglobin (HbF), which does not polymerize like hemoglobin S, thereby reducing sickling. Oxbryta, on the other hand, directly binds to hemoglobin S and stabilizes its oxygenated form, preventing the polymerization that causes sickling. These complementary mechanisms mean the two drugs can be used together for an additive therapeutic effect.
Yes, Oxbryta can be taken with or without food. There is no significant effect of food on the absorption of voxelotor. The key instruction is to swallow the tablets whole with a glass of water and not to split, crush, or chew them, as they have an unpleasant taste. Taking your dose at the same time each day helps maintain consistent blood levels of the medication.
If you miss a dose of Oxbryta, do not take a double dose. Simply continue with your regular schedule the next day. Do not try to compensate for the missed dose. Consistent daily use is important for the medicine to work effectively, so try to develop a routine that helps you remember to take it every day.
No, Oxbryta does not cure sickle cell disease. It is a disease-modifying treatment that helps manage the hemolytic anemia component of the condition. By reducing the sickling and destruction of red blood cells, it can improve hemoglobin levels and reduce the burden of chronic hemolysis. Currently, the only potential cure for sickle cell disease is a stem cell (bone marrow) transplant or emerging gene therapies. Oxbryta is an important part of the treatment toolkit for managing SCD symptoms and complications.
Yes, Oxbryta can interfere with certain blood tests, particularly those measuring hemoglobin fractions such as hemoglobin S percentage. Because voxelotor alters the oxygen-binding properties of hemoglobin, standard laboratory methods for measuring HbS may give inaccurate readings. Always inform your healthcare team and laboratory personnel that you are taking Oxbryta so they can use appropriate testing methods and interpret results correctly.
References
This article is based on the following peer-reviewed and authoritative sources:
- European Medicines Agency (EMA). Oxbryta (voxelotor) — Summary of Product Characteristics. EMA/CHMP, 2022. Available at: ema.europa.eu
- Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease (HOPE Trial). New England Journal of Medicine. 2019;381(6):509-519. doi: 10.1056/NEJMoa1903212
- U.S. Food and Drug Administration (FDA). Oxbryta (voxelotor) Prescribing Information. FDA, 2019 (updated 2023). Available at: fda.gov
- National Institute for Health and Care Excellence (NICE). Voxelotor for treating haemolytic anaemia in sickle cell disease. Technology Appraisal Guidance TA872, 2023.
- Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. The Lancet. 2017;390(10091):311-323. doi: 10.1016/S0140-6736(17)30193-9
- World Health Organization (WHO). Sickle Cell Disease: A Strategy for the WHO African Region. Report of the Regional Director, 2022.
- British National Formulary (BNF). Voxelotor. NICE Evidence Services, 2024.
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nature Reviews Disease Primers. 2018;4:18010. doi: 10.1038/nrdp.2018.10
Editorial Team
This article has been prepared and reviewed by the iMedic Medical Editorial Team, which comprises licensed physicians specializing in hematology, clinical pharmacology, and internal medicine. Our editorial process ensures all content is evidence-based, clinically accurate, and aligned with current international guidelines.
All content reviewed by board-certified hematologists and pharmacologists following EMA, FDA, and WHO guidelines. Evidence level: Grade 1A based on randomized controlled trials and systematic reviews.
We follow the GRADE evidence framework, declare no conflicts of interest, and accept no pharmaceutical company sponsorship. Our content is updated regularly to reflect the latest evidence and regulatory changes.